The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine. The compelling evidence is from work carried out at the research laboratories
As planned in the original protocol, the primary efficacy outcome will occur at Week 13, and does not change with this amendment. The primary efficacy endpoint is based
NeuroVive now holds approximately 10 percent of the shares in Isomerase. The overall aim with the acquisition is to strengthen the existing partnership and accelerate NeuroVive’s research and
These data further support the efficacy of BAREMSIS which has previously been shown to prevent PONV alone, and in combination with standard anti-emetics in pivotal Phase 3 prophylaxis
The Company plans to continue collecting and analyzing epidemiological data relating to OPANA ER. Endo's financial projections for 2016 did not assume approval of the sNDA. Endo executive
Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share. Cantor Fitzgerald & Co. acted as sole
The study published in the journal PLOS Computational Biology shows that flexible molecules, instead of rigid ones, as previously thought, can bind more effectively to the proteins causing
Fexapotide has completed 2 long-term large Phase 3 BPH studies in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and
Inovio is enrolling 125 subjects in a second stage of its phase I trial of INO-4212 after generating positive initial safety and immune response data in the first
Under the terms of the agreement, Jacobs is providing engineering, procurement and construction management (EPCM) services to increase the site’s production capacity by 70 percent and create a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.